Gemtuzumab ozogamicin
- Generic Name
- Gemtuzumab ozogamicin
- Brand Names
- Mylotarg
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 220578-59-6
- Unique Ingredient Identifier
- 8GZG754X6M
- Background
Gemtuzumab ozogamicin is a recombinant humanized IgG4 kappa antibody which is conjugated with calicheamicin derivative, a cytotoxic antitumor antibiotic isolated from fermentation of Micromonospora echinospora ssp. calichensis. Gemtuzumab ozogamicin has approximately 50% of the antibody loaded with 4-6 moles calicheamicin per mole of antibody . The antibody ...
- Indication
Indicated for the treatment of patients with CD33 positive acute myeloid leukemia in first relapse who are 60 years of age or older and who are not considered candidates for other cytotoxic chemotherapy. Indicated for the treatment of patients aged 2 years and older with CD33-positive AML who have experienced a relapse or who have not responded to initial tr...
- Associated Conditions
- Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia (AML), Relapsed Acute Myelogenous Leukemia (AML)
- Associated Therapies
- -
Cytarabine and Daunorubicin With or Without Gemtuzumab Ozogamicin in Treating Older Patients With Acute Myeloid Leukemia or Myelodysplastic Syndromes
- Conditions
- Interventions
- First Posted Date
- 2005-07-21
- Last Posted Date
- 2016-09-20
- Target Recruit Count
- 600
- Registration Number
- NCT00121303
- Locations
- 🇬🇧
University Hospital of Wales, Cardiff, Wales, United Kingdom
🇬🇧Medway Maritime Hospital, Gillingham Kent, England, United Kingdom
🇬🇧North Hampshire Hospital, Basingstoke, England, United Kingdom
CMA-676 in Treating Older Patients With Acute Myeloid Leukemia in First Relapse
- Conditions
- First Posted Date
- 2004-09-13
- Last Posted Date
- 2012-08-22
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 55
- Registration Number
- NCT00003673
- Locations
- 🇺🇸
Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, Illinois, United States
🇺🇸University of Chicago Cancer Research Center, Chicago, Illinois, United States
🇺🇸New England Medical Center Hospital, Boston, Massachusetts, United States
Gemtuzumab Ozogamicin in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia
- Conditions
- First Posted Date
- 2004-09-09
- Last Posted Date
- 2012-07-24
- Target Recruit Count
- 279
- Registration Number
- NCT00091234
- Locations
- 🇮🇹
Ospedale Binaghi, Cagliari, Italy
🇮🇹Ospedale Oncologico A. Businco, Cagliari, Italy
🇮🇹Ospedale Di Montefiascone, Montefiascone, Italy
CMA-676 in Treating Patients With Acute Myeloid Leukemia in First Relapse
- Conditions
- First Posted Date
- 2004-08-24
- Last Posted Date
- 2012-08-22
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 55
- Registration Number
- NCT00003131
- Locations
- 🇺🇸
Sylvester Cancer Center, University of Miami, Miami, Florida, United States
🇺🇸Beckman Research Institute, City of Hope, Duarte, California, United States
🇺🇸Marlene & Stewart Greenebaum Cancer Center, University of Maryland, Baltimore, Maryland, United States
Gemtuzumab Ozogamicin and Cyclosporine in Treating Older Patients With Relapsed Acute Myeloid Leukemia
- Conditions
- First Posted Date
- 2004-08-05
- Last Posted Date
- 2011-11-30
- Lead Sponsor
- Fred Hutchinson Cancer Center
- Registration Number
- NCT00089050
- Locations
- 🇺🇸
Fred Hutchinson Cancer Research Center, Seattle, Washington, United States
S0106 Cytarabine and Daunorubicin w/ or w/o Gemtuzumab Followed By HD Cytarabine and Either Gemtuzumab or Nothing in de Novo AML
- Conditions
- Interventions
- First Posted Date
- 2004-06-16
- Last Posted Date
- 2015-09-30
- Lead Sponsor
- SWOG Cancer Research Network
- Target Recruit Count
- 637
- Registration Number
- NCT00085709
- Locations
- 🇺🇸
Perry Memorial Hospital, Princeton, Illinois, United States
🇺🇸Cancer Center of Kansas-Independence, Independence, Kansas, United States
🇺🇸Munson Medical Center, Traverse City, Michigan, United States
Gemtuzumab Ozogamicin, Fludarabine, and Total-body Irradiation Followed by Peripheral Stem Cell or Bone Marrow Transplantation in Treating Patients With Advanced Acute Myeloid Leukemia or Myelodysplastic Syndrome
- Conditions
- First Posted Date
- 2004-03-25
- Last Posted Date
- 2010-04-02
- Lead Sponsor
- Fred Hutchinson Cancer Center
- Registration Number
- NCT00008151
- Locations
- 🇺🇸
Fred Hutchinson Cancer Research Center, Seattle, Washington, United States
Gemtuzumab Ozogamicin With or Without Chemotherapy in Treating Older Patients With Acute Myeloid Leukemia
- Conditions
- First Posted Date
- 2004-02-16
- Last Posted Date
- 2012-07-16
- Target Recruit Count
- 106
- Registration Number
- NCT00006122
- Locations
- 🇫🇷
Hotel Dieu de Paris, Paris, France
🇧🇪A.Z. St. Jan, Brugge, Belgium
🇦🇹Innsbruck Universitaetsklinik, Innsbruck, Austria
Idarubicin, Cytarabine, and Gemtuzumab Ozogamicin in Treating Patients With Previously Untreated High-Risk Myelodysplastic Syndrome or Acute Myeloid Leukemia Secondary to Myelodysplastic Syndrome
- Conditions
- First Posted Date
- 2004-02-11
- Last Posted Date
- 2012-07-16
- Target Recruit Count
- 31
- Registration Number
- NCT00077116
- Locations
- 🇨🇭
Universitaetsspital-Basel, Basel, Switzerland
🇧🇪AZ Sint-Jan, Brugge, Belgium
🇧🇪H. Hartziekenhuis - Roeselaere., Roeselare, Belgium
Gemtuzumab in Treating Patients With Myelodysplastic Syndrome
- Conditions
- First Posted Date
- 2004-01-14
- Last Posted Date
- 2013-12-19
- Lead Sponsor
- Jonsson Comprehensive Cancer Center
- Registration Number
- NCT00022321
- Locations
- 🇺🇸
Jonsson Comprehensive Cancer Center, UCLA, Los Angeles, California, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.